PASSAGE BIO INC. - COMMON STOCK

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

17 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

07 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

02 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

27 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

04 Aug 2021 21:00:00 By Nasdaq GlobeNewswire

Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

04 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

29 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

21 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Announces Key Executive Appointments

19 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

01 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming June Investor Conferences

26 May 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

11 May 2021 06:30:00 By Nasdaq GlobeNewswire

Passage Bio to Host Virtual R&D Event on May 17

10 May 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights

05 May 2021 07:00:02 By Nasdaq GlobeNewswire

Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia

03 May 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021

29 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

05 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

01 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming April Investor Conferences

25 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer

22 Mar 2021 07:00:00 By Nasdaq GlobeNewswire